Legato Capital Management LLC bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the second quarter, according to its most recent disclosure with the SEC. The fund bought 8,200 shares of the biotechnology company’s stock, valued at approximately $276,000.
A number of other institutional investors have also added to or reduced their stakes in SRPT. Principal Financial Group Inc. boosted its position in shares of Sarepta Therapeutics by 1.4% in the first quarter. Principal Financial Group Inc. now owns 9,455 shares of the biotechnology company’s stock worth $280,000 after buying an additional 129 shares during the last quarter. Sigma Planning Corp boosted its position in shares of Sarepta Therapeutics by 7.8% in the first quarter. Sigma Planning Corp now owns 12,895 shares of the biotechnology company’s stock worth $382,000 after buying an additional 930 shares during the last quarter. Bank of Montreal Can raised its stake in Sarepta Therapeutics by 1.0% in the first quarter. Bank of Montreal Can now owns 98,775 shares of the biotechnology company’s stock worth $2,924,000 after buying an additional 996 shares during the period. Bank of New York Mellon Corp raised its stake in Sarepta Therapeutics by 0.8% in the first quarter. Bank of New York Mellon Corp now owns 247,924 shares of the biotechnology company’s stock worth $7,339,000 after buying an additional 1,923 shares during the period. Finally, Stifel Financial Corp raised its stake in Sarepta Therapeutics by 19.3% in the first quarter. Stifel Financial Corp now owns 13,366 shares of the biotechnology company’s stock worth $397,000 after buying an additional 2,165 shares during the period. 64.58% of the stock is owned by institutional investors.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) traded up 3.57% during mid-day trading on Friday, hitting $38.34. 1,726,111 shares of the stock traded hands. Sarepta Therapeutics, Inc. has a 52 week low of $24.31 and a 52 week high of $63.73. The company’s market cap is $2.47 billion. The stock has a 50-day moving average of $37.03 and a 200-day moving average of $32.83.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million during the quarter, compared to analyst estimates of $22.52 million. During the same quarter in the prior year, the firm earned ($1.19) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% on a year-over-year basis. Analysts anticipate that Sarepta Therapeutics, Inc. will post ($1.16) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/08/12/legato-capital-management-llc-purchases-shares-of-8200-sarepta-therapeutics-inc-nasdaqsrpt-updated-updated.html.
SRPT has been the subject of several analyst reports. Cowen and Company restated a “buy” rating on shares of Sarepta Therapeutics in a research report on Friday, April 28th. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, July 27th. BidaskClub cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Robert W. Baird reiterated an “outperform” rating and issued a $102.00 price objective on shares of Sarepta Therapeutics in a research note on Sunday, April 23rd. Finally, Leerink Swann restated an “outperform” rating and issued a $52.00 price target (up from $47.00) on shares of Sarepta Therapeutics in a research note on Saturday, April 29th. Eight research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $61.28.
In related news, Director Edward M. Md Kaye sold 10,000 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $410,000.00. Following the transaction, the director now directly owns 62,471 shares in the company, valued at $2,561,311. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Alexander Cumbo sold 5,918 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $242,638.00. Following the completion of the transaction, the senior vice president now owns 22,793 shares in the company, valued at $934,513. The disclosure for this sale can be found here. Over the last quarter, insiders sold 78,056 shares of company stock worth $3,224,208. Corporate insiders own 9.60% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
What are top analysts saying about Sarepta Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sarepta Therapeutics Inc. and related companies.